ArticleFrontiers in oncology2025
To explore the risk factors of lymphovascular invasion in patients with upper tract urothelial carcinoma and construct a prediction model.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07321210 (Clinical Efficacy and Safety of Radical Nephroureterectomy With Versus Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Efficacy and Safety of Radical Nephroureterectomy With Versus Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma: A Multicenter, Prospective, Randomized Controlled Clinical Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: To explore the risk factors and construct a prediction model of the lymphovascular invasion (LVI) in patients with upper tract urothelial carcinoma (UTUC). Methods: Clinical data of 143 UTUC patients treated in our hospital during Jan. 2010 and Dec. 2022 were retrospectively analyzed. The patients were divided into LVI positive group and LVI negative group according to the postoperative lymphovascular conditions. Kaplan-Meier method was used to evaluate the overall survival (OS) and cancer-specific survival (CSS) of the two groups, and the survival curve was drawn. The correlation between LVI and inclusion indexes was analyzed using univariate and ultivariate. A prediction model was established and receiver operating characteristic (ROC) curve was drawn to analyze the diagnostic value. Results: The median survival time of LVI positive patients was 78 months (95%CI 44.47-111.53), lower than the 90months (95%CI 72.77-107.23) for LVI negative patients, and the 5-year OS of LVI positive patients was 53.0%, lower than that of LVI negative patients (79.6%). The difference was statistically significant (P=0.005). The 5-year CSS of LVI positive patients was 57.0%, lower than that of LVI negative patients (85.7%, P=0.009). The results of univariate analysis showed that there were statistically significant differences between the two groups (P < 0.05) in exfoliation cytology (P=0.044), hydronephrosis (P=0.015), preoperative fibrinogen level (P=0.003), lymph node status (P=0.014), pathological stage (P=0.001) and grade (P=0.047). Multivariate Logistic regression analysis showed that hydronephrosis (P=0.022), pathological stage (P < 0.001), lymph node status (P=0.025) and fibrinogen level (P=0.019) were independent factors influencing the occurrence of lymphovascular invasion, and the combination of four indexes above was better than any single index. the ROC curve showed that the area under the curve (AUC) of postoperative LVI was the largest when combined with the four predictors, and the AUC was 0.833 (95%CI 0.759-0.907). When the Youden index was 0.594, the sensitivity was 81.1%, and the specificity was 78.3%. Conclusion: Lymphovascular invasion is related to hydronephrosis, pathological stage, lymph node condition and fibrinogen level. Patients with preoperative hydronephrosis, high pathological stage, lymph node metastasis and high fibrinogen level were at higher risk of lymphovascular invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.